The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma.
Nicholas A. Butowski
Research Funding - Plexxikon
Howard Colman
No relevant relationships to disclose
John Frederick De Groot
No relevant relationships to disclose
Antonio Marcilio Padula Omuro
No relevant relationships to disclose
Lakshmi Nayak
No relevant relationships to disclose
Timothy F. Cloughesy
No relevant relationships to disclose
Adhirai Marimuthu
Employment or Leadership Position - Plexxikon
Arie Perry
No relevant relationships to disclose
Joanna J Phillips
No relevant relationships to disclose
Brian West
Employment or Leadership Position - Plexxikon
Michael Prados
No relevant relationships to disclose
Keith B. Nolop
Employment or Leadership Position - Plexxikon
Henry H Hsu
Employment or Leadership Position - Plexxikon
Keith L. Ligon
No relevant relationships to disclose